Entrada Therapeutics Director Trims Position by 2.8% in Form 4 Filing
Rhea-AI Filing Summary
Entrada Therapeutics (TRDA) – Form 4 insider transaction summary
Director and 10% owner Dr. Kush Parmar, through two affiliated venture funds, reported open-market sales totaling 125,000 common shares between 27 June and 1 July 2025. The sales were executed at prices ranging from $6.81 to $7.12 per share, generating roughly $0.9-1.2 million in proceeds (exact proceeds depend on final settlement).
- 5AM Ventures V, L.P. sold 92,891 shares across three trades and now owns 3,183,131 shares.
- 5AM Opportunities I, L.P. sold 32,109 shares and now owns 1,100,248 shares.
- The combined position after the transactions is approximately 4.28 million shares, meaning only about 2.8 % of their prior stake was divested.
No derivative securities were involved, and Dr. Parmar continues to disclaim beneficial ownership beyond his pecuniary interest. While insider selling often raises caution among investors, the modest percentage sold and the remaining large holding suggest routine portfolio rebalancing rather than a wholesale exit.
Positive
- Insider retains a substantial 4.28 million-share stake, demonstrating continued alignment with common shareholders and long-term interest.
Negative
- Director and 10% owner divested 125,000 shares (≈2.8% of position), which may be viewed as a mildly negative sentiment signal.
Insights
TL;DR: Small insider sale (≈2.8% of stake); signal is mildly negative but not materially impactful.
The three-day series of sales by funds managed by Director/10% owner Dr. Parmar reduces their aggregate position by 125k shares, leaving 4.28 million shares intact. Dollar proceeds are under $1.2 million, insignificant versus TRDA’s market cap. The share-price range near $7 aligns with recent trading averages, suggesting liquidity management rather than valuation call. Given continued >4 million-share ownership, strategic alignment remains. I view the filing as informational and neutral to slightly negative for sentiment but not financially material.
TL;DR: Governance risk low; disclosure complies with Section 16, sale size immaterial.
Form 4 is properly filed within two business days, indicating sound compliance. Dr. Parmar’s role as both Director and 10% owner increases scrutiny, yet his funds’ divestiture is small relative to holdings and carries transparent footnotes clarifying indirect ownership and disclaimers. No derivative activity or 10b5-1 plan is cited. From a governance lens, the action neither improves nor degrades oversight quality; investors should simply note ongoing liquidity management.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 18,578 | $7.1226 | $132K |
| Sale | Common Stock | 6,422 | $7.1226 | $46K |
| Sale | Common Stock | 18,578 | $6.8127 | $127K |
| Sale | Common Stock | 6,422 | $6.8127 | $44K |
| Sale | Common Stock | 55,735 | $6.91 | $385K |
| Sale | Common Stock | 19,265 | $6.91 | $133K |
Footnotes (1)
- Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.
